Teva presents new tardive dyskinesia data at psych congress 2024 from the impact-td registry, revealing differences in patient experience based on underlying psychiatric condition

Tel aviv, israel and parsippany, n.j., nov. 01, 2024 (globe newswire) -- teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced new patient- and physician-reported interim results from the phase 4 impact-td registry study, revealing differences between td patients with a psychotic disorder and those with a mood disorder. the impact-td registry is the largest study of its kind evaluating the holistic effects of td, showing real-world treatment patterns and outcomes with once-daily austedo® xr® (deutetrabenazine) extended-release tablets and twice-daily austedo (deutetrabenazine) tablets. teva also announced interim data from a patient-reported survey describing early, real-world experience with austedo xr. these findings are being presented at the psych congress 2024 taking place from october 29 – november 2 in boston, ma.
TEVA Ratings Summary
TEVA Quant Ranking